Three-year initiative brings together multidisciplinary teams to strengthen management of transthyretin amyloid cardiomyopathy (ATTR-CM)
The medical content describes Transthyretin amyloid cardiomyopathy, or ATTR-CM, as a serious and often underdiagnosed condition. It is caused by an abnormal protein buildup that prevents the left ventricle from relaxing and filling properly, thus impairing the heart’s function.
DALLAS, March 23, 2026 — Transthyretin amyloid cardiomyopathy, or ATTR‑CM, is a serious and often underdiagnosed condition caused by abnormal protein buildup that prevents the left ventricle from relaxing and filling properly, impairing the heart’s…
